104
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Diagnostic value of soluble programmed cell death protein-1 in type-1 autoimmune hepatitis in Egyptian children

, , &
Pages 59-65 | Received 26 Sep 2019, Accepted 17 Nov 2019, Published online: 25 Nov 2019

References

  • Pathak S, Kamat D. Autoimmune hepatitis in children. Pediatr Ann. 2018;47(2):e81–e86.
  • Liberal R, Vergani D, Mieli-Vergani G. Update on autoimmune hepatitis. J Clin Transl Hepatol. 2015;3(1):42.
  • Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepatitis. Lancet. 2013;382(9902):1433–1444.
  • Zamani MR, Aslani S, Salmaninejad A, et al. PD-1/PD-L and autoimmunity: a growing relationship. Cellul Immunol. 2016;310:27–41.
  • Aarslev K, Dige A, Greisen SR, et al. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scand J Gastroenterol. 2017;52(1):93–99.
  • Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–176.
  • Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–2213.
  • Huo TI, Lin HC, Wu JC, et al. Proposal of a modified Child‐Turcotte‐Pugh scoring system and comparison with the model for end‐stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl. 2006;12(1):65–71.
  • Freeman RB, Jr Wiesner RH, Roberts JP, et al. Improving liver allocation: MELD and PELD. Am J Transplant. 2004;4:114–131.
  • Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in cancer and autoimmunity. J Clin Immunol. 2014;153(1):145–152.
  • Behairy OG. Characteristics of autoimmune hepatitis in a sample of Egyptian children. Egypt Pediatr Assoc Gazette. 2017;65(4):108–113.
  • Mataki N, Kikuchi K, Kawai T, et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am J Gastroenterol. 2007;102(2):302.
  • Curran CS, Sharon E. PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. Semin Oncol. 2017;44(6):428–432.
  • Agina HA, Ehsan NA, Abd-Elaziz TA, et al. Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response. Clin Exp Hepatol. 2019;5(3):256.
  • Wang D, Zhou DA, Du Q, et al. Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C. Mol Med Rep. 2013;7(4):1197–1202.
  • Wan B, Nie H, Liu A, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177(12):8844–8850.
  • Czaja AJ. Under-evaluated or unassessed pathogenic pathways in autoimmune hepatitis and implications for future management. Dig Dis Sci. 2018;63(7):1706–1725.
  • Pen JJ, Keersmaecker BD, Heirman C, et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014;21(3):262.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.